PMID- 28705668
OWN - NLM
STAT- MEDLINE
DCOM- 20180727
LR  - 20180727
IS  - 1872-7913 (Electronic)
IS  - 0924-8579 (Linking)
VI  - 51
IP  - 1
DP  - 2018 Jan
TI  - In-vitro activity of the novel fluorocycline eravacycline against carbapenem
      non-susceptible Acinetobacter baumannii.
PG  - 62-64
LID - S0924-8579(17)30271-6 [pii]
LID - 10.1016/j.ijantimicag.2017.06.022 [doi]
AB  - The activity of eravacycline was compared with that of anti-Acinetobacter
      reference antimicrobials against carbapenem non-susceptible Acinetobacter
      baumannii isolates associated with an acquired OXA or up-regulation of the
      intrinsic OXA-51-like enzyme. Antimicrobial susceptibility testing was performed 
      by broth microdilution of 286 non-duplicate, carbapenem non-susceptible A.
      baumannii isolates to eravacycline, amikacin colistin, doxycycline, imipenem,
      levofloxacin, meropenem, minocycline, sulbactam, tigecycline and tobramycin.
      Eravacycline showed greater activity than the comparators of the tetracycline
      class, levofloxacin, amikacin, tobramycin and colistin. The eravacycline MIC50/90
      values were 0.5/1 mg/L and those for tigecycline, minocycline and doxycycline
      were 1/2, 4/8 and 32/ >/= 64 mg/L, respectively. In conclusion, eravacycline was 
      the most potent antibiotic of those tested against A. baumannii, including
      isolates that were resistant to sulbactam, imipenem/meropenem, levofloxacin and
      amikacin/tobramycin. Eravacycline has the potential to become a useful addition
      to the limited armamentarium of drugs that can be used to treat this problem
      pathogen.
CI  - Copyright (c) 2017 Elsevier B.V. and International Society of Chemotherapy. All
      rights reserved.
FAU - Seifert, Harald
AU  - Seifert H
AD  - Institute for Medical Microbiology, Immunology and Hygiene, University of
      Cologne, Cologne, Germany; German Center for Infection Research (DZIF), Partner
      Site Bonn-Cologne, Germany. Electronic address: harald.seifert@uni-koeln.de.
FAU - Stefanik, Danuta
AU  - Stefanik D
AD  - Institute for Medical Microbiology, Immunology and Hygiene, University of
      Cologne, Cologne, Germany.
FAU - Sutcliffe, Joyce A
AU  - Sutcliffe JA
AD  - Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA.
FAU - Higgins, Paul G
AU  - Higgins PG
AD  - Institute for Medical Microbiology, Immunology and Hygiene, University of
      Cologne, Cologne, Germany; German Center for Infection Research (DZIF), Partner
      Site Bonn-Cologne, Germany.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20170711
PL  - Netherlands
TA  - Int J Antimicrob Agents
JT  - International journal of antimicrobial agents
JID - 9111860
RN  - 0 (7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline)
RN  - 0 (Aminoglycosides)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Fluoroquinolones)
RN  - 0 (Tetracyclines)
RN  - 0 (beta-Lactams)
RN  - EC 3.5.2.6 (beta-Lactamases)
RN  - EC 3.5.2.6 (beta-lactamase OXA-51, Acinetobacter baumannii)
RN  - Z67X93HJG1 (Colistin)
SB  - IM
MH  - Acinetobacter Infections/*drug therapy/microbiology
MH  - Acinetobacter baumannii/*drug effects/genetics/isolation & purification
MH  - Aminoglycosides/pharmacology
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Colistin/pharmacology
MH  - Drug Resistance, Multiple, Bacterial/*genetics
MH  - Fluoroquinolones/pharmacology
MH  - Humans
MH  - Microbial Sensitivity Tests
MH  - Tetracyclines/*pharmacology
MH  - beta-Lactamases/genetics
MH  - beta-Lactams/pharmacology
OTO - NOTNLM
OT  - Colistin
OT  - International clone
OT  - Multidrug-resistance
OT  - Oxacillinase
OT  - Tetracycline
OT  - Tigecycline
EDAT- 2017/07/15 06:00
MHDA- 2018/07/28 06:00
CRDT- 2017/07/15 06:00
PHST- 2017/04/15 00:00 [received]
PHST- 2017/06/22 00:00 [revised]
PHST- 2017/06/24 00:00 [accepted]
PHST- 2017/07/15 06:00 [pubmed]
PHST- 2018/07/28 06:00 [medline]
PHST- 2017/07/15 06:00 [entrez]
AID - S0924-8579(17)30271-6 [pii]
AID - 10.1016/j.ijantimicag.2017.06.022 [doi]
PST - ppublish
SO  - Int J Antimicrob Agents. 2018 Jan;51(1):62-64. doi:
      10.1016/j.ijantimicag.2017.06.022. Epub 2017 Jul 11.